US2004002451A1PendingUtilityA1

Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing

53
Priority: Jun 20, 2002Filed: Jun 20, 2002Published: Jan 1, 2004
Est. expiryJun 20, 2022(expired)· nominal 20-yr term from priority
Inventors:Bruce KerwinByeong Seon ChangLei Shi
A61P 9/04A61P 3/10A61P 7/06A61P 39/00A61P 37/00A61P 43/00A61P 41/00A61P 9/10A61P 9/00A61P 35/02A61P 25/00A61P 25/08A61P 31/04A61P 25/04A61P 27/02A61P 25/02A61P 29/00A61P 35/00A61P 19/02A61P 1/04A61P 21/00A61P 1/18A61P 11/00A61P 17/06A61P 19/00A61P 17/02A61P 17/00A61K 47/10A61K 31/198A61K 47/183A61K 9/19A61K 9/0019A61K 38/1816A61K 47/12A61K 47/60A61K 47/26A61K 38/1793A61K 47/02Y02A50/30
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . An improved pharmaceutical formulation comprising a PEGsTNF-R1, wherein said formulation demonstrates improved stability and decreased viscosity (<400 cP) at concentrations of at least 45 mg/ml.

Join the waitlist — get patent alerts

Track US2004002451A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.